These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 36672405)
1. Targeting Interleukin-6/Glycoprotein-130 Signaling by Raloxifene or SC144 Enhances Paclitaxel Efficacy in Pancreatic Cancer. Hering NA; Günzler E; Arndt M; Zibell M; Lauscher JC; Kreis ME; Beyer K; Seeliger H; Pozios I Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672405 [TBL] [Abstract][Full Text] [Related]
2. Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144. Pozios I; Hering NA; Guenzler E; Arndt M; Elezkurtaj S; Knösel T; Bruns CJ; Margonis GA; Beyer K; Seeliger H J Cancer Res Clin Oncol; 2023 Jan; 149(1):271-280. PubMed ID: 36495330 [TBL] [Abstract][Full Text] [Related]
3. Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling. Pozios I; Seel NN; Hering NA; Hartmann L; Liu V; Camaj P; Müller MH; Lee LD; Bruns CJ; Kreis ME; Seeliger H Cell Oncol (Dordr); 2021 Feb; 44(1):167-177. PubMed ID: 32940862 [TBL] [Abstract][Full Text] [Related]
4. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling. Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601 [TBL] [Abstract][Full Text] [Related]
5. Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells. Chen X; Tian J; Su GH; Lin J Curr Cancer Drug Targets; 2019; 19(5):417-427. PubMed ID: 29714141 [TBL] [Abstract][Full Text] [Related]
6. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Xu S; Grande F; Garofalo A; Neamati N Mol Cancer Ther; 2013 Jun; 12(6):937-49. PubMed ID: 23536726 [TBL] [Abstract][Full Text] [Related]
7. Combination effects of SC144 and cytotoxic anticancer agents. Oshima T; Cao X; Grande F; Yamada R; Garofalo A; Louie S; Neamati N Anticancer Drugs; 2009 Jun; 20(5):312-20. PubMed ID: 19322070 [TBL] [Abstract][Full Text] [Related]
8. Inflammation as a chemoprevention target in asbestos-induced malignant mesothelioma. Kadariya Y; Sementino E; Shrestha U; Gorman G; White JM; Ross EA; Clapper ML; Neamati N; Miller MS; Testa JR Carcinogenesis; 2022 Dec; 43(12):1137-1148. PubMed ID: 36355620 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763 [TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells. Momeny M; Alishahi Z; Eyvani H; Esmaeili F; Zaghal A; Ghaffari P; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH Cell Oncol (Dordr); 2020 Feb; 43(1):81-93. PubMed ID: 31512195 [TBL] [Abstract][Full Text] [Related]
11. Synergistic inhibition of GP130 and ERK signaling blocks chemoresistant bladder cancer cell growth. Li X; He S; Tian Y; Weiss RM; Martin DT Cell Signal; 2019 Nov; 63():109381. PubMed ID: 31374291 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. Awasthi N; Monahan S; Stefaniak A; Schwarz MA; Schwarz RE Oncotarget; 2018 Jan; 9(4):5274-5286. PubMed ID: 29435178 [TBL] [Abstract][Full Text] [Related]
13. Reversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells. Xu L; Lei J; Jiang D; Zhou L; Wang S; Fan W Cancer Biol Ther; 2015; 16(12):1794-801. PubMed ID: 26529585 [TBL] [Abstract][Full Text] [Related]
14. Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma. Le Large TYS; Bijlsma MF; El Hassouni B; Mantini G; Lagerweij T; Henneman AA; Funel N; Kok B; Pham TV; de Haas R; Morelli L; Knol JC; Piersma SR; Kazemier G; van Laarhoven HWM; Giovannetti E; Jimenez CR J Exp Clin Cancer Res; 2021 Mar; 40(1):91. PubMed ID: 33750427 [TBL] [Abstract][Full Text] [Related]
15. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer. Li S; Tian J; Zhang H; Zhou S; Wang X; Zhang L; Yang J; Zhang Z; Ji Z Apoptosis; 2018 Jun; 23(5-6):356-374. PubMed ID: 29777330 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. Sun JD; Liu Q; Ahluwalia D; Li W; Meng F; Wang Y; Bhupathi D; Ruprell AS; Hart CP Cancer Biol Ther; 2015; 16(3):438-49. PubMed ID: 25679067 [TBL] [Abstract][Full Text] [Related]
17. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352 [TBL] [Abstract][Full Text] [Related]
18. KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma. Li SS; Jiang WL; Xiao WQ; Li K; Zhang YF; Guo XY; Dai YQ; Zhao QY; Jiang MJ; Lu ZJ; Wan R World J Gastrointest Oncol; 2019 Aug; 11(8):599-621. PubMed ID: 31435462 [TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer. Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980 [TBL] [Abstract][Full Text] [Related]
20. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice. Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]